India, Sept. 21 -- Shares of GRAIL Inc. (GRAL) are back above $100 as the company approaches a watershed moment on Wednesday.
GRAIL is a healthcare company whose flagship product, Galleri, is designed to detect multiple types of cancer at an early stage using what the company calls multi-cancer early detection (MCED) technology.
Galleri is a blood test designed to screen for many of the deadliest cancers before they cause symptoms, including cancers for which no recommended screening tests currently exist, according to the company.
Available as a laboratory-developed test in the U.S. since mid-2021, Galleri is facing its first major FDA regulatory test on September 23, 2026, when an FDA advisory committee is scheduled to review the compa...